Making AAVs the Go-To for Making Gene Therapies Go

Q4 Biochemistry, Genetics and Molecular Biology

Genetic Engineering & Biotechnology News Pub Date : 2023-10-01 DOI:10.1089/gen.43.10.19

MaryAnn Labant

引用次数: 0

Abstract

Genetic Engineering & Biotechnology NewsVol. 43, No. 10 Drug DiscoveryMaking AAVs the Go-To for Making Gene Therapies GoIf adeno-associated viruses are to deliver more gene therapies, they will need to address issues such as load capacity, targetability, immunogenicity, and scalabilityMaryAnn LabantMaryAnn LabantSearch for more papers by this authorPublished Online:13 Oct 2023https://doi.org/10.1089/gen.43.10.19AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 43Issue 10Oct 2023 Information© 2023 by GEN PublishingTo cite this article:MaryAnn Labant.Making AAVs the Go-To for Making Gene Therapies Go.Genetic Engineering & Biotechnology News.Oct 2023.46-48, 50, 52.http://doi.org/10.1089/gen.43.10.19Published in Volume: 43 Issue 10: October 13, 2023PDF download

查看原文本刊更多论文

让aav成为基因治疗的首选

基因工程与生物技术新闻卷。43、第10位药物发现制造aav是制造基因疗法的首选如果腺相关病毒要提供更多的基因疗法，它们将需要解决诸如负载能力、靶向性、免疫原性、和可扩展性MaryAnn LabantMaryAnn labant搜索本文作者的更多论文出版在线:2023年10月13日https://doi.org/10.1089/gen.43.10.19AboutSectionsView文章查看全文pdf /EPUB权限和citationspermissions下载CitationsTrack citations添加到收藏回到出版物ShareShare onFacebookTwitterLinked InRedditEmail查看文章figuresreferencesrelateddetails Volume 43Issue 10Oct 2023信息©2023 by GEN publishing引用本文:MaryAnn Labant。让aav成为基因治疗的首选。基因工程与生物技术新闻。2023.10月46- 48,50,52 .http://doi.org/10.1089/gen.43.10.19Published in Volume: 43 Issue 10: October 13, 2023PDF下载

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genetic Engineering & Biotechnology News 工程技术-生物工程与应用微生物

CiteScore

0.20

自引率

0.00%

发文量

210

审稿时长

3-6 weeks

期刊介绍： Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Launched in 1980, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth, and career opportunities. With nearly 40 years of publishing experience, GEN maintains unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry. Through its cornerstone Magazine, high-frequency newsletters, and dynamic suite of multimedia resources, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their organization’s success. GEN’s breadth of editorial coverage is unrivaled in the industry, providing exclusive coverage of the entire bioproduct lifecycle across five key pillars: Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Gene Editing.